It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
Granules India receives 1 observation from USFDA for Chantilly facility
Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing plants by volume
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
Strengthening capabilities in Peptide Therapeutics and CDMO services
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder in adults and pediatric patients aged six years and older
Subscribe To Our Newsletter & Stay Updated
